Relationship between anticancer activity and stereochemistry of saldach ligands and their iron(III) complexes.
(R,R)-, (S,S)- and (R,S)-N,N'-bis(salicylidene)-1,2-diaminocyclohexane (saldach) and their iron(III) complexes were screened for anticancer activity against MCF-7 and MDA-MB 231 breast cancer as well as HT-29 colon carcinoma cells. Antiproliferative effects depended on the presence of the central atom iron but were independent on the configuration at the saldach ligand. While the free ligands were inactive, the iron(III) derivatives displayed anticancer activity within a concentration range of 1 to 5 microM irrespective of the used cell line. At 5 microM they were even more active than cis-platin. A mode of action comparable to cis-platin can be excluded because it is very likely that the DNA is not the primary target of [Fe(III) (saldach)] complexes.
Hille
Annegret
A
Institute of Pharmacy, Freie Universität Berlin, Berlin, Germany.
Gust
Ronald
R
D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005290:Ferric Compounds / Q000737:chemistry*; D006801:Humans; D008024:Ligands; D015394:Molecular Structure; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D005290:Ferric Compounds; D008024:Ligands